Ajulemic acid - Corbus Pharmaceuticals

Drug Profile

Ajulemic acid - Corbus Pharmaceuticals

Alternative Names: Anabasum; CPL-7075; CT-3; DMH-11C; HU-239; IP-751; JBT-101; Lenabasum; Resunab

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Massachusetts Medical School
  • Developer Cervelo Pharmaceuticals; Corbus Pharmaceuticals; Indevus Pharmaceuticals; National Institute of Arthritis and Musculoskeletal and Skin Diseases; University of Erlangen-Nuremberg; University of Pennsylvania; University of Siena
  • Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Antirheumatics; Cannabinoids; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists; Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis; Dermatomyositis; Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic scleroderma
  • Phase II Cystic fibrosis; Dermatomyositis; Systemic lupus erythematosus
  • Phase I Inflammation
  • Preclinical Pulmonary fibrosis
  • Discontinued Interstitial cystitis; Muscle spasticity; Neuropathic pain; Pain; Poisoning

Most Recent Events

  • 20 Jul 2018 Ajulemic acid - Corbus Pharmaceuticals receives Orphan Drug status for Dermatomyositis in USA
  • 13 Jun 2018 Efficacy and adverse events data from an open-label extension phase II trial in Dermatomyositis and Systemic scleroderma presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 13 Jun 2018 Updated efficacy and adverse events data from an open-label extension phase II trials in Dermatomyositis and Systemic scleroderma released by Corbus Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top